ABSTRACT

Background: Diabetes growing steadily all over the world irrespective of health care efforts to prevent it. Many anti-diabetics were present and new generations continue to be introduced into the market. Glibenclamide is an antidiabetic, which exerts its therapeutic effect by triggering insulin secretion. The olive tree has been recognized for a long time as a source of bioactive polyphenols which have an anti-hyperglycemic effect on diabetic rats. Aim of the work: To study the effect of extra virgin olive oil (EVOO) on the pharmacodynamics of glibenclamide in diabetic rats. Materials and methods: This study was carried on 50 Male adult albino rats (200-250g). They were divided into 2 groups. Group 1: included “10 rats” served as “Control group” received single i.v. injection of citrate buffer, in a volume equal to that used as a solvent for streptozotocin (STZ) used to induce diabetes in test groups. Group 2: included diabetic rats“40 rats” which were injected by single intraperitoneal injection of a freshly prepared solution of STZ (dissolved in cold 0.01 M citrate buffer, pH 4.5) in a dose of 55 mg/kg body weight. The diabetic rats were divided into 4 subgroups. Group A: Diabetic rats concurrently treated with saline. Group B: Rats of this group were treated orally by 0.3 mg/kg of glibenclamide daily for 6 weeks. Group C: Rats of this group were treated orally by (1mL/100gbw) of Extra Virgin Olive Oil (EVOO) daily for 6 weeks. Group D: Rats of this group were treated orally by (0.3 mg/kg) of glibenclamide and (1mL/100g.bw) of Extra Virgin Olive Oil (EVOO) daily for 6 weeks. Then blood samples were collected and examined for serum glucose, lipid profile, liver and kidney functions. Rats were sacrificed; livers were obtained and prepared for histological examination. Results: There was statistically significant increase of glucose, triglycerides, low density lipoprotein, total cholesterol, alanine transaminase, aspartate transaminase, urea and creatinine, and significant decrease of high density lipoprotein in the diabetic group when compared to control group. Administration of either glibenclamide or EVOO or combination together was associated with improvement of biochemical alterations associated with diabetes with superiority of glibenclamide. Histopathological, normal control revealed normal structure of the liver and kidney, while in diabetic group, the liver tissues showed loss of normal lobular architecture, with liver cell apoptosis (the cells are shrunken, the nuclei were dark stained, fragmented or faint). Each of glibenclamide, EVOO was able to prevent histopathological abnormalities in both liver and kidney. Conclusion: The combination of EVOO with glibenclamide represents a valuable combination to improve diabetes and its complications. Keywords: Antidiabetic; Glibenclamide; Extra-virgin olive oil; Diabetes mellitus
Publication date: 01/08/2020

https://ijbpas.com/pdf/2020/August/MS_IJBPAS_2020_5165.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2020/9.8.5165